GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 402 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 402 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the sale, the chief financial officer now owns 5,044 shares of the company’s stock, valued at $454,212.20. This represents a 7.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $362,565.79.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total value of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.

GeneDx Stock Up 7.3 %

WGS stock opened at $97.44 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The stock has a market capitalization of $2.73 billion, a P/E ratio of -49.71 and a beta of 1.91. The business has a 50-day moving average of $84.59 and a 200-day moving average of $70.97. GeneDx Holdings Corp. has a fifty-two week low of $8.03 and a fifty-two week high of $115.60.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. On average, sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. MCF Advisors LLC boosted its position in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after purchasing an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its position in GeneDx by 877.8% during the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after purchasing an additional 316 shares during the last quarter. Global Retirement Partners LLC acquired a new position in GeneDx during the fourth quarter valued at approximately $28,000. Lazard Asset Management LLC acquired a new position in GeneDx during the fourth quarter valued at approximately $35,000. Finally, Comerica Bank acquired a new position in GeneDx during the fourth quarter valued at approximately $50,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on WGS shares. The Goldman Sachs Group increased their price target on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. TD Cowen increased their price target on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.